Cargando…

Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas

MYC rearrangements usually confer aggressive biological behavior to large B-cell lymphomas. In this study, we aimed to evaluate the relevance of LMO2 detection to the clinical approach to these tumors. First, the ability of LMO2 loss of expression to recognize the presence of MYC rearrangements was...

Descripción completa

Detalles Bibliográficos
Autores principales: Vazquez, Ivonne, Papaleo, Natalia, Garcia, Eugenia, Salido, Marta, Salar, Antonio, Hernandez, Silvia, Calvo, Xavier, Colomo, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226002/
https://www.ncbi.nlm.nih.gov/pubmed/32260556
http://dx.doi.org/10.3390/cancers12040884
_version_ 1783534185385820160
author Vazquez, Ivonne
Papaleo, Natalia
Garcia, Eugenia
Salido, Marta
Salar, Antonio
Hernandez, Silvia
Calvo, Xavier
Colomo, Luis
author_facet Vazquez, Ivonne
Papaleo, Natalia
Garcia, Eugenia
Salido, Marta
Salar, Antonio
Hernandez, Silvia
Calvo, Xavier
Colomo, Luis
author_sort Vazquez, Ivonne
collection PubMed
description MYC rearrangements usually confer aggressive biological behavior to large B-cell lymphomas. In this study, we aimed to evaluate the relevance of LMO2 detection to the clinical approach to these tumors. First, the ability of LMO2 loss of expression to recognize the presence of MYC rearrangements was evaluated. A series of 365 samples obtained from 351 patients, including 28 Burkitt lymphoma, 230 diffuse large B-cell lymphoma, 30 high-grade B-cell lymphoma with MYC and BCL2/BCL6 rearrangements, eight high-grade B-cell lymphoma-NOS, 43 transformed diffuse large B-cell lymphoma, and 26 high-grade follicular lymphomas was analyzed. Among the CD10-positive tumors prospectively analyzed in whole tissue sections, LMO2 negative expression obtained values of 88% sensitivity, 94% specificity, and 93% accuracy, proving the utility of LMO2 to screen MYC rearrangements. In addition, survival analyses were performed in a series of 155 patients. As per univariate analyses, the prognosis relevance of LMO2 was as useful as that of the diagnostic categories, MYC rearrangements, and MYC immunohistochemistry. Multivariate models revealed that both LMO2 (hazard ratio 0.51 p = 0.02) and IPI (hazard ratio 1.67 p < 0.005) were independent variables predicting overall survival. Finally, MYC and LMO2 mRNA expression were analyzed in a small group of cases. Taken together, these findings show the interest of LMO2 testing in large B-cell lymphomas.
format Online
Article
Text
id pubmed-7226002
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72260022020-05-18 Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas Vazquez, Ivonne Papaleo, Natalia Garcia, Eugenia Salido, Marta Salar, Antonio Hernandez, Silvia Calvo, Xavier Colomo, Luis Cancers (Basel) Article MYC rearrangements usually confer aggressive biological behavior to large B-cell lymphomas. In this study, we aimed to evaluate the relevance of LMO2 detection to the clinical approach to these tumors. First, the ability of LMO2 loss of expression to recognize the presence of MYC rearrangements was evaluated. A series of 365 samples obtained from 351 patients, including 28 Burkitt lymphoma, 230 diffuse large B-cell lymphoma, 30 high-grade B-cell lymphoma with MYC and BCL2/BCL6 rearrangements, eight high-grade B-cell lymphoma-NOS, 43 transformed diffuse large B-cell lymphoma, and 26 high-grade follicular lymphomas was analyzed. Among the CD10-positive tumors prospectively analyzed in whole tissue sections, LMO2 negative expression obtained values of 88% sensitivity, 94% specificity, and 93% accuracy, proving the utility of LMO2 to screen MYC rearrangements. In addition, survival analyses were performed in a series of 155 patients. As per univariate analyses, the prognosis relevance of LMO2 was as useful as that of the diagnostic categories, MYC rearrangements, and MYC immunohistochemistry. Multivariate models revealed that both LMO2 (hazard ratio 0.51 p = 0.02) and IPI (hazard ratio 1.67 p < 0.005) were independent variables predicting overall survival. Finally, MYC and LMO2 mRNA expression were analyzed in a small group of cases. Taken together, these findings show the interest of LMO2 testing in large B-cell lymphomas. MDPI 2020-04-05 /pmc/articles/PMC7226002/ /pubmed/32260556 http://dx.doi.org/10.3390/cancers12040884 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Vazquez, Ivonne
Papaleo, Natalia
Garcia, Eugenia
Salido, Marta
Salar, Antonio
Hernandez, Silvia
Calvo, Xavier
Colomo, Luis
Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas
title Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas
title_full Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas
title_fullStr Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas
title_full_unstemmed Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas
title_short Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas
title_sort clinical interest of lmo2 testing for the diagnosis of aggressive large b-cell lymphomas
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226002/
https://www.ncbi.nlm.nih.gov/pubmed/32260556
http://dx.doi.org/10.3390/cancers12040884
work_keys_str_mv AT vazquezivonne clinicalinterestoflmo2testingforthediagnosisofaggressivelargebcelllymphomas
AT papaleonatalia clinicalinterestoflmo2testingforthediagnosisofaggressivelargebcelllymphomas
AT garciaeugenia clinicalinterestoflmo2testingforthediagnosisofaggressivelargebcelllymphomas
AT salidomarta clinicalinterestoflmo2testingforthediagnosisofaggressivelargebcelllymphomas
AT salarantonio clinicalinterestoflmo2testingforthediagnosisofaggressivelargebcelllymphomas
AT hernandezsilvia clinicalinterestoflmo2testingforthediagnosisofaggressivelargebcelllymphomas
AT calvoxavier clinicalinterestoflmo2testingforthediagnosisofaggressivelargebcelllymphomas
AT colomoluis clinicalinterestoflmo2testingforthediagnosisofaggressivelargebcelllymphomas